Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.06 billion, focuses on developing and commercializing innovative medicines to address unmet ...

A replay of both events will be available in the Investors section on the Company's website at www.soleno.life.

SINGAPORE - Growing teens have voracious appetites, but Teo Zi Yee, 17, and David Lucas Soo, 13, feel starved constantly and cannot be left unattended with food. They have Prader-Willi syndrome (PWS) ...

Obesity drug developer Aardvark Therapeutics (AARD) has filed for a $100M initial public offering. Aardvark (AARD) didn't disclose any terms in its SEC filing, but indicated in its filing fee schedule ...

A pioneering new treatment promises to tackle a wider range of cancers, with fewer side-effects than conventional radiotherapy. It also takes less than a second. In a series of vast underground ...

Colette Love makes the Radio 4 Appeal on behalf of the Prader-Willi Syndrome Association UK. The charity runs a phone line for families affected by the condition. Show more Colette Love makes the ...

“The Rett syndrome community in Europe is excited by the prospect of having an available treatment option. Rett syndrome has a significant impact on people living with this condition, and also ...

ARD-101 is currently in Phase 3 development for hyperphagia associated with Prader-Willi Syndrome and Aardvark intends to evaluate ... inhibitor, for the treatment of obesity and obesity-related ...

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...

Key players like Pfizer, Soleno Therapeutics, Harmony Biosciences, and others are driving innovation in the Prader-Willi Syndrome treatment landscape. LAS VEGAS , NV ...